Icatibant Acetate
Product description
Icatibant Acetate is a selective competitive antagonist for the bradykinin B2 receptor. It is indicated for the treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare disorder resulting in periodic attacks of acute edema. It is characterized by a deficiency of functional C1 esterase inhibitor that leads to the overproduction of bradykinin, which triggers vasodilation, vascular permeability, and edema. Icatibant Acetate inhibits bradykinin from binding to the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.
Read more
Specifications
| CAS Registry Number | 130308-48-4 |
|---|---|
| Categories | APIs (Active Pharmaceutical Ingredients); Contract Services - Contract ServicesContract Manufacturing; APIs (Active Pharmaceutical Ingredients)Peptides |
| Sales markets | Middle East Region (e.g. UAE); North America (USA, Canada); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore) |
| Supplied from | Switzerland; United States |
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation